MetaCap

BriaCell Therapeutics (BCTX) vs NanoViricides (NNVC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 10.2% versus a loss of 61.7%. Over five years, NNVC leads with a -76.5% price change compared with -97.0% for BCTX. NanoViricides is the larger company by market cap ($29.1 million vs $26.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCTX-61.75%NNVC-10.24%
+64%-4%-72%
Nov 21, 20251 yearNov 20, 2026
BCTX-97.12%NNVC-75.16%
+18%-43%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCTX versus NNVC key metrics
MetricBCTXNNVC
Share price$3.06$1.14
Market cap$26.72M$29.13M
1-day change-3.32%-2.56%
YTD return-56.96%+0.88%
1-year return-61.75%-10.24%
5-year return-97.00%-76.54%
EPS (TTM)$-6.97$-0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-34.90M$-8.22M
52-week high$13.09$1.93
52-week low$2.60$0.85
Distance from 52-week high-76.62%-40.93%
Analyst consensus—strong_buy
Avg. price target upside—+426.32%
Average volume250.81K356.86K
Shares outstanding8.73M25.55M
Employees—7
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed BCTX by 51.5 percentage points over the past year.

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

BCTX vs NNVC FAQ

Which is bigger, BriaCell Therapeutics or NanoViricides?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, BCTX or NNVC?

NNVC returned -10.24% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.

Are BriaCell Therapeutics and NanoViricides in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons